- INmune
Bio is a diversified, clinical stage immunology company developing novel
therapies targeting distinct parts of a patient’s innate immune system to
fight disease
- Drug
candidates INKmune and INB03 may be used to treat cancer; XPro1595 targets
neuroinflammation as a cause of Alzheimer’s disease
- The
company was awarded a $1 million “Part the Cloud” grant from the
Alzheimer’s Association to advance XPro1595 research
- INmune
recently entered a common stock purchase agreement for up to $20 million
with Lincoln Park Capital
INmune Bio Inc. (NASDAQ: INMB), an immunology company
focused on developing treatments that harness the patient’s innate immune
system to fight disease, is pursuing several drug candidates that utilize a
precision therapy approach to treat unsolved problems in medicine. Among the
company’s active drug candidates are INKmune and INB03, which may be used to
treat cancer, and XPro1595, which targets neuroinflammation as a cause of
Alzheimer’s disease (http://ibn.fm/uX3hO).
INmune Bio recently posted its Q1 2019 financial results in
a shareholder update, which highlighted the achievement of becoming the first
biotechnology company to close an initial public offering (IPO) in 2019 and
commence trading on the Nasdaq Capital Market (http://ibn.fm/NGhG0).
Importantly, INmune Bio was recognized by the Alzheimer’s Association with a
“Part the Cloud” award that included a $1 million grant to further research
into XPro1595 and the potential hope that it may bring to millions of patients
with Alzheimer’s disease.
“2019 has marked a transformative period for INmune Bio, as
the first biotech of the year to close its IPO and list on the Nasdaq,” RJ
Tesi, M.D, INmune Bio’s chief executive officer, stated in a news release. “We
are focused on advancing our clinical programs for the foreseeable future.”
XPro1595 targets the microglial immune cells of the brain
that are activated in many Alzheimer’s disease patients. These microglial cells
are a cause of neuroinflammation that can kill nerve cells and promote synaptic
dysfunction – the cause of dementia in Alzheimer’s. A phase I clinical trial in
patients with Alzheimer’s disease, supported by the Alzheimer’s Association
grant, is expected to be initiated in the summer of 2019.
Upcoming catalysts for INmune Bio include advancements in
several clinical trials featuring INB03 and INKmune – both of which are focused
on “taking the brakes off” the body’s innate immune system to become a powerful
weapon in the fight against cancer. INB03 is a checkpoint inhibitor that
targets cells resistant to immunotherapy to instead become therapeutically
effective; INKmune primes a patient’s own natural killer cells to move from a
resting state to an active state to attack and eliminate residual disease
(lingering cancer cells) after cancer therapy.
A recently published Zacks Small-Cap Research report values
INmune Bio at $19 a share. David Bautz, PhD, who wrote the report, said that
Zacks (http://ibn.fm/f2ejk)
is “excited by the early clinical data INmune has compiled thus far and believe
that the innate immune system is a currently untapped resource for extending
the lives of cancer patients.”
INmune Bio also announced a common stock purchase agreement
with Lincoln Park Capital Fund LLC, a Chicago-based institutional investor, for
up to $20 million (subject to the terms of the agreements with Lincoln Park),
which includes an initial investment of $300,000 (http://ibn.fm/3Zu9H). The
investment is in addition to an earlier investment made by Lincoln Park during
INmune Bio’s first round of funding in 2017, when the company was private.
“This financing agreement provides flexibility to
opportunistically access capital at our option under favorable terms to advance
our innate immune therapies in cancer and Alzheimer’s disease,” added David
Moss, CFO of INmune Bio, noting that the funds will specifically help advance
the company’s drug development pipeline into phase II clinical trials.
In addition, there was an insider-led round of investment
totaling approximately $4.6 million, including investments by the company’s CEO
and CFO.
For more information, visit the company’s website at www.INmuneBio.com
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
